BR9810366A - Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek - Google Patents
Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mekInfo
- Publication number
- BR9810366A BR9810366A BR9810366-0A BR9810366A BR9810366A BR 9810366 A BR9810366 A BR 9810366A BR 9810366 A BR9810366 A BR 9810366A BR 9810366 A BR9810366 A BR 9810366A
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- mek inhibitors
- bromo
- benzhydroxyamide
- iodo phenylamino
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 3
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 title abstract 2
- -1 4-iodo phenylamino benzhydroxyamide Chemical compound 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- VVTCLTONLVZMDI-UHFFFAOYSA-N 2-anilino-n-hydroxybenzamide Chemical class ONC(=O)C1=CC=CC=C1NC1=CC=CC=C1 VVTCLTONLVZMDI-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Abstract
Patente de Invenção: <B>"DERIVADOS DE áCIDO 4-BROMO OU 4-IODO FENILAMINO BENZIDROXÎMICO E SEU USO COMO INIBIDORES DE MEK"<D>. Trata-se de derivados de ácido fenilamino benzidroxâmico de fórmula (I) na qual R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~ e R~ 6~ são hidrogênio ou grupos substituintes tais como alquila, e onde R~ 7~ é hidrogênio ou um radical orgânico, os quais são potentes inibidores de MEK e, como tais, são eficazes no tratamento de câncer e outras doenças proliferativas tais como psoríase e restenose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5144097P | 1997-07-01 | 1997-07-01 | |
PCT/US1998/013106 WO1999001426A1 (en) | 1997-07-01 | 1998-06-24 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9810366A true BR9810366A (pt) | 2000-08-29 |
Family
ID=21971339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9810366-0A BR9810366A (pt) | 1997-07-01 | 1998-06-24 | Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP0993439B1 (pt) |
JP (1) | JP2002511092A (pt) |
KR (1) | KR20010014362A (pt) |
CN (1) | CN1163475C (pt) |
AR (1) | AR016762A1 (pt) |
AT (1) | ATE277895T1 (pt) |
AU (1) | AU757046B2 (pt) |
BR (1) | BR9810366A (pt) |
CA (1) | CA2290506C (pt) |
CO (1) | CO4940442A1 (pt) |
DE (1) | DE69826662T2 (pt) |
ES (1) | ES2229515T3 (pt) |
HR (1) | HRP980368A2 (pt) |
HU (1) | HUP0003731A3 (pt) |
IL (1) | IL132840A (pt) |
IS (1) | IS5256A (pt) |
MY (1) | MY120994A (pt) |
NO (1) | NO315271B1 (pt) |
NZ (1) | NZ501276A (pt) |
PE (1) | PE97999A1 (pt) |
PL (1) | PL337698A1 (pt) |
PT (1) | PT993439E (pt) |
TW (1) | TW396149B (pt) |
UY (1) | UY25076A1 (pt) |
WO (1) | WO1999001426A1 (pt) |
ZA (1) | ZA985728B (pt) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
AU2180500A (en) * | 1998-12-15 | 2000-07-03 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
HUP0104933A3 (en) * | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
EE200100373A (et) | 1999-01-13 | 2002-10-15 | Warner-Lambert Company | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena |
GEP20032999B (en) * | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
CA2348236A1 (en) * | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
EP1144371B1 (en) | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
DE60017109T2 (de) * | 1999-04-21 | 2006-01-12 | Warner-Lambert Co. Llc | Verfahren zur herstellung von 2-(n-phenylalmino)benzoesäure |
US6686499B1 (en) | 1999-04-21 | 2004-02-03 | Warner-Lambert Company | Method for making 2-(N-phenylamino)benzoic acids |
GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910580D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
JP2003504400A (ja) * | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた慢性痛の治療方法 |
EP1339702A1 (en) | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
BR0109188A (pt) * | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
DE10017480A1 (de) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
SK2072003A3 (en) * | 2000-08-25 | 2004-01-08 | Warner Lambert Co | Process for making N-aryl-anthranilic acids and their derivatives |
EP1365796A2 (en) | 2000-09-01 | 2003-12-03 | Van Andel Institute | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
JP2004517059A (ja) | 2000-11-02 | 2004-06-10 | アストラゼネカ アクチボラグ | 抗腫瘍剤用の4−置換キノリン類 |
WO2002076496A1 (en) * | 2001-03-22 | 2002-10-03 | Van Andel Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
MXPA04005527A (es) | 2002-01-23 | 2005-03-23 | Warner Lambert Co | ESTERES HIDROXIMATO DEL áCIDO N-(4-FENIL SUSTITUIDO)-ANTRANILICO. |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
UA77765C2 (en) | 2002-03-13 | 2007-01-15 | Array Biopharma Inc | N3 alkylated derivatives of benzimidazole as mek inhibitors |
EP1651214B1 (en) | 2003-07-24 | 2009-09-16 | Warner-Lambert Company LLC | Benzimidazole derivatives as mek inhibitors |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
WO2005040098A1 (en) | 2003-10-21 | 2005-05-06 | Warner-Lambert Company Llc | Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
CA2545660C (en) | 2003-11-19 | 2013-06-04 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
CA2561516A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
JP4927733B2 (ja) | 2004-08-17 | 2012-05-09 | エフ.ホフマン−ラ ロシュ アーゲー | 置換ヒダントイン |
TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
ES2444866T3 (es) | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
DE602006014951D1 (de) | 2005-04-06 | 2010-07-29 | Chugai Pharmaceutical Co Ltd | Verfahren zur herstellung von 2,3,4-trifluor-5-(iod- oder -brom)benzoesäure |
TWI441637B (zh) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
HRP20110498T1 (hr) | 2005-10-07 | 2011-08-31 | Exelixis | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti |
US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
EP2049546B1 (en) | 2006-07-06 | 2010-12-29 | Array Biopharma, Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
DK2054418T3 (da) | 2006-07-06 | 2012-02-27 | Array Biopharma Inc | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer |
ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
EP1908751A1 (en) * | 2006-10-03 | 2008-04-09 | EOS S.p.A. | N-hydroxy benzamides with antitumour activity |
US7696218B2 (en) | 2006-10-23 | 2010-04-13 | Takeda San Diego, Inc. | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
JPWO2008075741A1 (ja) * | 2006-12-20 | 2010-04-15 | 国立大学法人 長崎大学 | 糖尿病治療剤及び予防剤 |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
WO2009006567A2 (en) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
EP2188276B1 (en) | 2007-08-16 | 2012-03-28 | F. Hoffmann-La Roche AG | Substituted hydantoins |
BRPI0820696A2 (pt) | 2007-12-20 | 2019-09-24 | Hoffmann La Roche | hidantoínas substituídas como inibidores de cinase de mek |
AU2009204025B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
CN101932565B (zh) | 2008-01-09 | 2013-06-12 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷 |
WO2009143224A2 (en) | 2008-05-20 | 2009-11-26 | Fox Chase Center Center | Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research |
AU2009279940B2 (en) | 2008-08-04 | 2014-01-16 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
PL2346827T3 (pl) | 2008-08-27 | 2014-04-30 | Leo Pharma As | Pochodne pirydyny jako inhibitory receptora VEGFR-2 i białkowej kinazy tyrozynowej |
EP2346818B1 (en) | 2008-11-10 | 2012-12-05 | Bayer Intellectual Property GmbH | Substituted sulphonamido phenoxybenzamides |
CA2777304A1 (en) | 2009-10-21 | 2011-04-28 | Marion Hitchcock | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
US20120269803A1 (en) | 2009-10-21 | 2012-10-25 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
CA2816188A1 (en) | 2010-10-29 | 2012-05-03 | Marion Hitchcock | Substituted phenoxypyridines |
CN103380212B (zh) | 2010-12-22 | 2017-04-05 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
WO2012135781A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
PL2694073T3 (pl) | 2011-04-01 | 2019-06-28 | Genentech, Inc. | Kombinacje inhibitorów AKT i MEK do leczenia nowotworu |
ES2597052T3 (es) | 2011-05-25 | 2017-01-13 | Université Paris Descartes | Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
EP2909188B1 (en) | 2012-10-12 | 2018-03-07 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
WO2015038704A1 (en) | 2013-09-11 | 2015-03-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions for preparing cardiomyocytes |
WO2015108907A2 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
PT3114214T (pt) | 2014-03-04 | 2024-01-03 | Fate Therapeutics Inc | Métodos de reprogramação melhorados e plataformas de cultura celular |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
CA2974381A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
WO2017066634A1 (en) | 2015-10-16 | 2017-04-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
EP3371314B1 (en) | 2015-11-04 | 2023-07-05 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス,インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
JP7616817B2 (ja) | 2016-01-20 | 2025-01-17 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
CN110139854A (zh) * | 2016-07-28 | 2019-08-16 | 约翰斯霍普金斯大学 | O-取代异羟肟酸 |
US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
CN107556201B (zh) * | 2017-09-08 | 2020-10-27 | 山西智创药研科技有限公司 | 一种制备间氨基苯酚的工艺方法 |
US20220087989A1 (en) * | 2018-11-20 | 2022-03-24 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |
MA54741A (fr) * | 2018-11-20 | 2021-11-24 | Nflection Therapeutics Inc | Composés thiényl-aniline destinés au traitement d'affections de la peau |
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
-
1998
- 1998-06-24 JP JP50722899A patent/JP2002511092A/ja not_active Abandoned
- 1998-06-24 ES ES98932830T patent/ES2229515T3/es not_active Expired - Lifetime
- 1998-06-24 AT AT98932830T patent/ATE277895T1/de not_active IP Right Cessation
- 1998-06-24 CN CNB988067501A patent/CN1163475C/zh not_active Expired - Fee Related
- 1998-06-24 PT PT98932830T patent/PT993439E/pt unknown
- 1998-06-24 CA CA002290506A patent/CA2290506C/en not_active Expired - Fee Related
- 1998-06-24 IL IL13284098A patent/IL132840A/en not_active IP Right Cessation
- 1998-06-24 DE DE69826662T patent/DE69826662T2/de not_active Expired - Lifetime
- 1998-06-24 HU HU0003731A patent/HUP0003731A3/hu unknown
- 1998-06-24 EP EP98932830A patent/EP0993439B1/en not_active Expired - Lifetime
- 1998-06-24 AU AU82627/98A patent/AU757046B2/en not_active Ceased
- 1998-06-24 NZ NZ501276A patent/NZ501276A/xx unknown
- 1998-06-24 WO PCT/US1998/013106 patent/WO1999001426A1/en not_active Application Discontinuation
- 1998-06-24 BR BR9810366-0A patent/BR9810366A/pt not_active Application Discontinuation
- 1998-06-24 PL PL98337698A patent/PL337698A1/xx unknown
- 1998-06-24 KR KR1019997012519A patent/KR20010014362A/ko not_active Ceased
- 1998-06-25 TW TW087110252A patent/TW396149B/zh not_active IP Right Cessation
- 1998-06-29 MY MYPI98002946A patent/MY120994A/en unknown
- 1998-06-30 UY UY25076A patent/UY25076A1/es not_active Application Discontinuation
- 1998-06-30 PE PE1998000579A patent/PE97999A1/es not_active Application Discontinuation
- 1998-06-30 AR ARP980103165A patent/AR016762A1/es unknown
- 1998-06-30 HR HR60/051,440A patent/HRP980368A2/hr not_active Application Discontinuation
- 1998-06-30 ZA ZA985728A patent/ZA985728B/xx unknown
- 1998-06-30 CO CO98036883A patent/CO4940442A1/es unknown
-
1999
- 1999-11-19 IS IS5256A patent/IS5256A/is unknown
- 1999-12-27 NO NO19996491A patent/NO315271B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
ES2229515T3 (es) | 2005-04-16 |
PE97999A1 (es) | 1999-11-05 |
CO4940442A1 (es) | 2000-07-24 |
MY120994A (en) | 2005-12-30 |
KR20010014362A (ko) | 2001-02-26 |
CA2290506A1 (en) | 1999-01-14 |
DE69826662T2 (de) | 2005-02-17 |
NO996491D0 (no) | 1999-12-27 |
IL132840A (en) | 2004-12-15 |
PL337698A1 (en) | 2000-08-28 |
AU8262798A (en) | 1999-01-25 |
CN1163475C (zh) | 2004-08-25 |
CN1261877A (zh) | 2000-08-02 |
WO1999001426A1 (en) | 1999-01-14 |
IL132840A0 (en) | 2001-03-19 |
HUP0003731A3 (en) | 2002-11-28 |
DE69826662D1 (de) | 2004-11-04 |
EP0993439B1 (en) | 2004-09-29 |
TW396149B (en) | 2000-07-01 |
IS5256A (is) | 1999-11-19 |
PT993439E (pt) | 2004-12-31 |
CA2290506C (en) | 2005-12-27 |
HUP0003731A2 (hu) | 2001-04-28 |
UY25076A1 (es) | 1998-12-01 |
AU757046B2 (en) | 2003-01-30 |
EP0993439A1 (en) | 2000-04-19 |
ZA985728B (en) | 1999-01-27 |
AR016762A1 (es) | 2001-08-01 |
JP2002511092A (ja) | 2002-04-09 |
NZ501276A (en) | 2000-10-27 |
HRP980368A2 (en) | 1999-04-30 |
NO315271B1 (no) | 2003-08-11 |
NO996491L (no) | 1999-12-29 |
ATE277895T1 (de) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9810366A (pt) | Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek | |
BR9907886A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd. | |
BRPI0416692A (pt) | inibidores heterocìclicos de mek e métodos de emprego destes | |
BR0312464A (pt) | Inibidores de tirosina quinases | |
PT662958E (pt) | Derivados do acido 1-(2-oxo-acetil)-piperidina-2-carboxilico como sensibilizadores de celulas cancerosas resistentes a farmacos multiplos | |
FI970810A0 (fi) | Ionipolymeerejä sisältäviä biologisesti aktiivisia anioneja | |
BR0108396A (pt) | Derivados de pirimidina-4-0na como inibidores de ldl-pla(2) | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
BR9810385A (pt) | Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
CY1110521T1 (el) | Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας | |
BR9710737A (pt) | Pentafluorobenzenosulfonamidas e análogos. | |
BR0208373A (pt) | Inibidores da tirosina cinase | |
BR9916223A (pt) | 4-ariloxindóis como inibidores de cinases de proteìna jnk | |
BR0007589A (pt) | Inibidores da proliferação de células | |
AR008853A1 (es) | Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos | |
BR0316296A (pt) | Compostos lapacone e seus métodos de uso | |
ES2101858T3 (es) | Derivados de geneserina como inhibidores de colinesterasa. | |
AR021695A1 (es) | 4,5-pirazinoxindoles, composicion farmaceutica y uso | |
BR0008302A (pt) | Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma | |
AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
PT1109560E (pt) | Compostos uteis como inidores de aicarft |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI. |